JP2025510725A5 - - Google Patents
Info
- Publication number
- JP2025510725A5 JP2025510725A5 JP2024556113A JP2024556113A JP2025510725A5 JP 2025510725 A5 JP2025510725 A5 JP 2025510725A5 JP 2024556113 A JP2024556113 A JP 2024556113A JP 2024556113 A JP2024556113 A JP 2024556113A JP 2025510725 A5 JP2025510725 A5 JP 2025510725A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical preparation
- cyclodextrin
- melphalanflufenamide
- preparation according
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2204171.9A GB202204171D0 (en) | 2022-03-24 | 2022-03-24 | Novel formulations |
| GB2204171.9 | 2022-03-24 | ||
| PCT/EP2023/057729 WO2023180565A1 (en) | 2022-03-24 | 2023-03-24 | Formulations comprising melphalan flufenamide and cyclodextrin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025510725A JP2025510725A (ja) | 2025-04-15 |
| JP2025510725A5 true JP2025510725A5 (https=) | 2026-02-19 |
Family
ID=81449463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024556113A Pending JP2025510725A (ja) | 2022-03-24 | 2023-03-24 | メルファランフルフェナミド及びシクロデキストリンを含む製剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250205155A1 (https=) |
| EP (1) | EP4499049A1 (https=) |
| JP (1) | JP2025510725A (https=) |
| KR (1) | KR20240161664A (https=) |
| CN (1) | CN119053323A (https=) |
| AU (1) | AU2023241241A1 (https=) |
| CA (1) | CA3245985A1 (https=) |
| GB (1) | GB202204171D0 (https=) |
| IL (1) | IL315551A (https=) |
| MX (1) | MX2024011654A (https=) |
| WO (1) | WO2023180565A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025233915A1 (en) * | 2024-05-10 | 2025-11-13 | Allgenesis Biotherapeutics Inc. | Use of an agonist of formyl peptide receptors 1 and 2 for treating ocular inflammatory diseases |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0002202D0 (sv) | 2000-06-13 | 2000-06-13 | Karolinska Innovations Ab | New peptides |
| DK2701720T3 (en) | 2011-04-28 | 2017-10-09 | Oncopeptides Ab | Lyophilized preparation with cytotoxic dipeptides |
| SMT202000058T1 (it) | 2012-10-26 | 2020-03-13 | Oncopeptides Ab | Preparazioni liofilizzate di melfalan flufenammide |
| GB201507903D0 (en) | 2015-05-08 | 2015-06-24 | Oncopeptides Ab | Process for preparation of nitrogen mustard derivatives |
| US12152087B2 (en) | 2018-10-18 | 2024-11-26 | Oncopeptides Innovation Ab | Deuterated melflufen compounds |
| GB201905477D0 (en) | 2019-04-17 | 2019-05-29 | Oncopeptides Ab | Novel formulations |
-
2022
- 2022-03-24 GB GBGB2204171.9A patent/GB202204171D0/en not_active Ceased
-
2023
- 2023-03-24 WO PCT/EP2023/057729 patent/WO2023180565A1/en not_active Ceased
- 2023-03-24 JP JP2024556113A patent/JP2025510725A/ja active Pending
- 2023-03-24 IL IL315551A patent/IL315551A/en unknown
- 2023-03-24 CN CN202380035203.1A patent/CN119053323A/zh active Pending
- 2023-03-24 CA CA3245985A patent/CA3245985A1/en active Pending
- 2023-03-24 US US18/849,977 patent/US20250205155A1/en active Pending
- 2023-03-24 EP EP23720032.4A patent/EP4499049A1/en active Pending
- 2023-03-24 KR KR1020247034012A patent/KR20240161664A/ko active Pending
- 2023-03-24 AU AU2023241241A patent/AU2023241241A1/en active Pending
-
2024
- 2024-09-23 MX MX2024011654A patent/MX2024011654A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5670335B2 (ja) | ベンダムスチン液体製剤 | |
| JP7753097B2 (ja) | Ｈｓｐ９０結合コンジュゲート及びその製剤 | |
| CA3142960C (en) | A formulation of a conjugate of a tubulysin analog to a cell-binding molecule | |
| JP2001247459A (ja) | 癌の組み合わせ療法 | |
| JP2020143143A (ja) | 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法 | |
| RU2734930C2 (ru) | Режимы дозирования мелфлуфена для раковых заболеваний | |
| JP2020532562A5 (https=) | ||
| WO2020240514A1 (en) | Stable formulations of indocyanine green | |
| JP6502507B2 (ja) | スルホンアミド系医薬組成物の調製方法 | |
| JP2024175025A (ja) | 組織の灌流の増加における使用のためのイノシトールリン酸化合物 | |
| JP2025510725A5 (https=) | ||
| JP2024537864A5 (https=) | ||
| CN106456572A (zh) | 用于增加mhc‑i表达的姜黄根醇化合物 | |
| RU2005133665A (ru) | Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств | |
| JP2021527682A (ja) | 放射性医薬品用のソマトスタチンアナログを含む組成物 | |
| US20140056996A1 (en) | Antitumoral combination comprising cabazitaxel and cisplatin | |
| JP6051315B2 (ja) | 乾癬を処置するためのピドチモドの使用 | |
| JP2019525922A (ja) | 癌を治療するための方法および組成物 | |
| CN111107837A (zh) | 包含西普尼莫德的肠胃外制剂 | |
| JP2000507207A (ja) | 複合注射剤 | |
| ES2774101T3 (es) | Cabazitaxel y su uso para tratar cáncer | |
| JP2019525924A5 (https=) | ||
| US20200315233A1 (en) | Methods and compositions for treatment of hypercalciuria and nephrolithiasis | |
| JP2009046450A (ja) | 抗がん剤へのヒアルロン酸添加 | |
| JPH08165236A (ja) | 下痢の予防及び治療剤 |